X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare GSK Pharma with Orchid Chemicals - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GSK PHARMA vs ORCHID PHARMA LTD - Comparison Results

GSK PHARMA    Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

ORCHID PHARMA LTD 
   Change

Orchid Chemicals & Pharmaceuticals Ltd. (Orchid) is today a globally recognized, integrated pharmaceutical company with core competencies in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms as well... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GSK PHARMA ORCHID PHARMA LTD GSK PHARMA/
ORCHID PHARMA LTD
 
P/E (TTM) x 63.8 -0.5 - View Chart
P/BV x 10.3 0.4 2,704.4% View Chart
Dividend Yield % 1.2 0.0 -  

Financials

 GSK PHARMA   ORCHID PHARMA LTD
EQUITY SHARE DATA
    GSK PHARMA
Mar-17
ORCHID PHARMA LTD
Sep-13
GSK PHARMA/
ORCHID PHARMA LTD
5-Yr Chart
Click to enlarge
High Rs3,838194 1,978.4%   
Low Rs2,63735 7,534.3%   
Sales per share (Unadj.) Rs354.2276.5 128.1%  
Earnings per share (Unadj.) Rs39.8-79.2 -50.2%  
Cash flow per share (Unadj.) Rs42.9-43.5 -98.7%  
Dividends per share (Unadj.) Rs30.000-  
Dividend yield (eoy) %0.90-  
Book value per share (Unadj.) Rs236.953.9 439.3%  
Shares outstanding (eoy) m84.7070.45 120.2%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x9.10.4 2,207.0%   
Avg P/E ratio x81.4-1.4 -5,632.4%  
P/CF ratio (eoy) x75.5-2.6 -2,865.9%  
Price / Book Value ratio x13.72.1 643.7%  
Dividend payout %75.40-   
Avg Mkt Cap Rs m274,2168,067 3,399.4%   
No. of employees `0004.72.8 167.8%   
Total wages/salary Rs m4,8302,527 191.1%   
Avg. sales/employee Rs Th6,387.06,956.1 91.8%   
Avg. wages/employee Rs Th1,028.3902.5 113.9%   
Avg. net profit/employee Rs Th717.1-1,993.0 -36.0%   
INCOME DATA
Net Sales Rs m30,00019,477 154.0%  
Other income Rs m728407 178.8%   
Total revenues Rs m30,72819,884 154.5%   
Gross profit Rs m4,1901,103 380.0%  
Depreciation Rs m2632,519 10.4%   
Interest Rs m05,227 0.0%   
Profit before tax Rs m4,655-6,236 -74.6%   
Minority Interest Rs m020 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m457511 89.4%   
Tax Rs m1,744-125 -1,393.0%   
Profit after tax Rs m3,368-5,580 -60.4%  
Gross profit margin %14.05.7 246.7%  
Effective tax rate %37.52.0 1,866.1%   
Net profit margin %11.2-28.7 -39.2%  
BALANCE SHEET DATA
Current assets Rs m16,74211,014 152.0%   
Current liabilities Rs m7,20232,060 22.5%   
Net working cap to sales %31.8-108.1 -29.4%  
Current ratio x2.30.3 676.6%  
Inventory Days Days5295 54.6%  
Debtors Days Days2134 61.9%  
Net fixed assets Rs m8,63529,440 29.3%   
Share capital Rs m847705 120.2%   
"Free" reserves Rs m19,2222,043 941.0%   
Net worth Rs m20,0693,800 528.1%   
Long term debt Rs m109,018 0.1%   
Total assets Rs m30,03846,510 64.6%  
Interest coverage xNM-0.2-  
Debt to equity ratio x02.4 0.0%  
Sales to assets ratio x1.00.4 238.5%   
Return on assets %11.2-0.8 -1,475.2%  
Return on equity %16.8-146.9 -11.4%  
Return on capital %25.5-3.7 -681.7%  
Exports to sales %037.9 0.0%   
Imports to sales %022.6 0.0%   
Exports (fob) Rs mNA7,378 0.0%   
Imports (cif) Rs mNA4,406 0.0%   
Fx inflow Rs m5287,513 7.0%   
Fx outflow Rs m7,1935,649 127.3%   
Net fx Rs m-6,6651,865 -357.5%   
CASH FLOW
From Operations Rs m2,3601,682 140.3%  
From Investments Rs m3,008-9,860 -30.5%  
From Financial Activity Rs m-5,1086,644 -76.9%  
Net Cashflow Rs m260-1,535 -17.0%  

Share Holding

Indian Promoters % 0.0 32.3 -  
Foreign collaborators % 50.7 0.0 -  
Indian inst/Mut Fund % 10.2 4.6 221.7%  
FIIs % 23.8 3.3 721.2%  
ADR/GDR % 0.0 4.6 -  
Free float % 15.4 55.3 27.8%  
Shareholders   102,036 84,811 120.3%  
Pledged promoter(s) holding % 0.0 54.9 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GSK PHARMA With:   DR. REDDYS LAB  IPCA LABS  JUBILANT LIFE SCIENCES  VENUS REMEDIES  STERLING BIOTECH  

Compare GSK PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Global Stock Markets Rebound After Sharp Weekly Drop(RoundUp)

Global financial markets rallied this week and brushed aside a rise in global borrowing costs while the dollar hit its lowest level since 2014.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

Here's What You Should Do in this Market Crash(The 5 Minute Wrapup)

Feb 6, 2018

The market correction has provided a golden opportunity to buy five high-quality safe stocks.

As the Market Corrects... It's Time to Buy More(Smart Contrarian)

Feb 5, 2018

The recent sell off in the stock market offers buying opportunity in some quality small caps.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

When Small is Not Always Beautiful(Chart Of The Day)

Feb 6, 2018

Big companies enjoying tax deductions and exemptions have an edge over the small companies.

What Should Mutual Fund Investors Do After LTCG Tax Norms(Outside View)

Feb 6, 2018

PersonalFN explain what investors should after LTCG tax norms.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

GSK PHARMA SHARE PRICE


Feb 16, 2018 (Close)

TRACK GSK PHARMA

  • Track your investment in GSK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

GSK PHARMA 8-QTR ANALYSIS

COMPARE GSK PHARMA WITH

MARKET STATS